Evaxion A/S (NASDAQ:EVAX) Coverage Initiated at JonesTrading

Analysts at JonesTrading started coverage on shares of Evaxion A/S (NASDAQ:EVAX) in a report released on Tuesday,Benzinga reports. The firm set a “buy” rating and a $10.00 price target on the stock. JonesTrading’s price target indicates a potential upside of 178.32% from the company’s current price.

A number of other brokerages have also issued reports on EVAX. Maxim Group began coverage on Evaxion A/S in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th. Lake Street Capital dropped their price target on Evaxion A/S from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday. Finally, HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Evaxion A/S in a research note on Monday. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Evaxion A/S Trading Up 16.7%

EVAX stock traded up $0.51 during trading on Tuesday, hitting $3.59. The company had a trading volume of 28,746 shares, compared to its average volume of 52,085. Evaxion A/S has a 52-week low of $1.20 and a 52-week high of $12.15. The company has a 50 day simple moving average of $3.87 and a 200-day simple moving average of $4.63. The firm has a market capitalization of $29.97 million, a P/E ratio of -2.65 and a beta of 0.28. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.41.

Evaxion A/S (NASDAQ:EVAX) last released its quarterly earnings data on Thursday, March 5th. The company reported $0.30 earnings per share (EPS) for the quarter. As a group, research analysts forecast that Evaxion A/S will post -0.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Evaxion A/S

A number of institutional investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. bought a new position in Evaxion A/S in the fourth quarter worth about $38,000. Wesbanco Bank Inc. purchased a new position in shares of Evaxion A/S in the 4th quarter worth approximately $48,000. Finally, SmartHarvest Portfolios LLC bought a new position in shares of Evaxion A/S during the 4th quarter worth approximately $72,000. Institutional investors own 11.04% of the company’s stock.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.